News

Pharmaceutical Technology10m
Sarepta halts Elevidys shipments following FDA pressure
Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.
Sarepta Stock Falls. Why It’s Caving Into the FDA and What Comes Next.
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.
STAT57m
In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy
Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.
Asian markets are mixed and Japan's shares slip after election leaves Ishiba's future in doubt
Asian markets are mixed after U.S. stock indexes hit new records on Monday. Oil prices fell and U.S. futures were little ...
US stock futures little changed as investors await more earnings reports
U.S. stock futures are little changed as investors await more earnings reports. The broad S&P 500 and tech-heavy Nasdaq scored record highs to start the week amid solid earnings reports from Domino's ...
pharmaphorum23m
Sarepta backs down and pauses Elevidys shipments
The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...